Precision Medicine News and Research

RSS

New stroke guidelines could help pave the way for precision rehabilitation

A University of Maryland School of Medicine (UMSOM) stroke rehabilitation specialist helped develop new recommendations for studying molecular biomarkers associated with recovery from stroke.

28 Aug 2026

Newly developed radiotheranostic pair identifies and treats renal tumors

A newly developed radiotheranostic pair, 68Ga/177Lu-NYM096, can identify tumors and effectively deliver targeted radiotherapy to patients with metastatic clear cell renal cell carcinoma (ccRCC).

28 Aug 2026

UCSF scientists build largest molecular interaction map for autism

For more than two decades, researchers have identified hundreds of genes that increase the risk of autism spectrum disorder (ASD).

28 Aug 2026

Review explores complex links between obesity and cardiovascular diseases

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Obesity, given its strong association with cardiovascular diseases (CVDs), is a major global public health issue attracting increasing attention.

27 Aug 2026

Computer model could streamline design of protein degraders

A team of Weill Cornell Medicine investigators has developed a computer model that will help scientists more efficiently develop protein-destroying therapies, a newer type of treatment that is particularly promising for cancer.

27 Aug 2026

FDA endorses alpha-synuclein biomarker for Parkinson’s clinical trials

Critical Path Institute® (C-Path) today announced the publication of "Regulatory endorsement for the application of alpha-synuclein seed amplification assay (αSyn-SAA) as a susceptibility and risk biomarker for clinical trials targeting synucleinopathies" in the Journal of Parkinson's Disease, marking a significant milestone for its Critical Path for Parkinson's consortium.

25 Aug 2026

Younger lung cancer patients show more targetable gene alterations

Younger adults with non-small cell lung cancer are significantly more likely than older patients to have genetic alterations that can be matched with targeted therapies, according to a large international study led in part by researchers at Sylvester Comprehensive Cancer Center part of the University of Miami Miller School of Medicine.

21 Aug 2026

A single blood test could offer a glimpse of disease risk years in advance

Machine learning-derived cellular aging clocks mapped more than 7,000 plasma proteins to over 40 cell types, revealing marked differences in how individual cell populations age. These blood-based signatures were associated with future risks of Alzheimer’s disease, ALS, lung cancer, type 2 diabetes, and mortality across follow-up extending to 15 years.

19 Aug 2026

Multi-source data-driven machine learning improves lung cancer care

Lung cancer remains one of the malignancies with the highest incidence and mortality worldwide.

17 Aug 2026

Computational pipeline uncovers subtype specific targets for cervical cancer

A new study presents a multi-layered strategy for identifying cell-surface targets that could help guide more precise antibody-drug conjugate (ADC) development for cervical cancer, with different targets showing distinct potential across tumor subtypes.

17 Aug 2026

Understanding how maternal age impacts offspring health across different species

In humans and many other animals, a mother's age can affect the physical and behavioral characteristics of the next generation.

17 Aug 2026

Polydatin reduces ulcerative colitis by regulating intestinal immune cells

Ulcerative colitis (UC) is a chronic inflammatory bowel disease in which recurrent intestinal inflammation can be difficult to control over the long term.

17 Aug 2026

Tagomics introduces LiquiPath, a first-in-class cfDNA-based blood test for multi-organ drug safety monitoring

Tagomics Ltd., a pioneering precision medicine company, today announced the launch of LiquiPath™, a cross-species, multi-organ "liquid pathology" platform, for non-invasive drug safety monitoring.

From Tagomics Ltd. 17 Aug 2026

PolyU develops AI Virtual Patient Simulation System for precision cancer care

A research team at The Hong Kong Polytechnic University (PolyU) has developed a patient-centric "Artificial Intelligence (AI) Virtual Patient Simulation System", overcoming the limitations of conventional static diagnosis.

14 Aug 2026

AI-based "tissue clocks" measure the biological age of human organs

AI-based "tissue clocks" can estimate the biological age of human organs from histological images, researchers at the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences and the Ludwig Boltzmann Institute for Network Medicine (LBI-NetMed) at the University of Vienna showed.

14 Aug 2026

Outfitting cells in "invisibility cloaks" could offer a novel approach to treating diabetes

Outfitting cells in "invisibility cloaks" may offer an easier, less damaging treatment pathway for people with diabetes undergoing cell therapy, according to researchers at Penn State.

14 Aug 2026

Researchers find unexpected protein regulator of leukemia drug sensitivity

How cells respond to the leukemia drug 6-thioguanine still holds surprises: A new study, led by researchers from CeMM and the University of Oxford identifies NUDT5 as an unexpected regulator of drug sensitivity and reveals that its role has nothing to do with its enzymatic activity.

12 Aug 2026

Molecular mapping reveals hidden cellular programs in heart transplant rejection

A new study that explores gene expression during heart transplant rejection marks a step forward for precision medicine approaches to treat organ rejection.

12 Aug 2026

Immune cell interaction timing impacts glioblastoma treatment response

A joint research team led by Professor Sungsu Park of Sungkyunkwan University and Professor Sun-Ha Paek of Seoul National University College of Medicine has demonstrated for the first time that the sequence in which immune cells interact with cancer cells can critically influence the therapeutic response in glioblastoma.

10 Aug 2026

Circular eccDNA shows potential to predict early-stage LUAD recurrence

LUAD is the most common histological subtype of lung cancer. Although surgery can be curative for patients diagnosed at an early stage, approximately 30%-50% develop recurrence or aggressive metastasis within five years.

10 Aug 2026